ArticleFrontiers in oncology2024

Efficacy and prognosis biomarker of locally advanced ESCC patients treated with neoadjuvant chemotherapy and anti-PD-1 immunotherapy.

Shuman Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.